Hematology Today—March 23, 2026

LucidQuest

2 days ago

This week’s Hematology update highlights hemophilia gene therapy supply constraints and regional expansion, alongside frontline immunotherapy advances in Hodgkin lymphoma, regulatory momentum in LATAM and China, and continued late-stage pipeline activity in AML and DLBCL.
Dive deeper

🧬 HEMGENIX supply disruption highlights gene therapy manufacturing strain [1] [Global • 17 Mar 2026]

https://newsroom.csl.com/2026-03-17-Our-Commitment-to-the-Hemophilia-B-Community-An-Update-on-HEMGENIX-R-etranacogene-dezaparvovec-drlb-Availability
Context: HEMGENIX is a one-time AAV gene therapy for adults with hemophilia B.
Key point: CSL reported a temporary global stockout, attributing delays to manufacturing complexity rather than safety or efficacy issues.
Implication: May influence access timelines and payer logistics for gene therapy delivery.

💊 MINJUVI expands footprint in follicular lymphoma across LATAM [2][3] [LATAM • 17 Mar 2026]

https://investors.knighttx.com/English/news/news-details/2026/Knight-Therapeutics-Announces-Approval-of-Additional-Indication-for-MINJUVI-tafasitamab-in-Brazil/default.aspx
Context: Tafasitamab is a CD19-targeting monoclonal antibody used in B-cell malignancies.
Key point: Approved in Brazil and under review in Argentina and Mexico for relapsed/refractory follicular lymphoma in combination with lenalidomide and rituximab.
Implication: Introduces competition that may affect pricing and formulary access.

🧪 Nivolumab moves into frontline Hodgkin lymphoma [4] [US • 20 Mar 2026]

https://www.medscape.com/viewarticle/fda-oks-upfront-nivolumab-chemo-classic-hodgkin-lymphoma-2026a10008lu
Context: Study CA209-8UT randomized ~1,000 patients to nivolumab + AVD vs brentuximab vedotin + AVD.
Key point: FDA approved nivolumab + AVD for first-line treatment of stage III–IV classical Hodgkin lymphoma based on PFS improvement (HR 0.42).
Implication: May shift standard-of-care regimens in advanced Hodgkin lymphoma.

🩸 MIRACLE AML trial advancing toward interim readout [5] [US/EU • 19 Mar 2026]

https://moleculin.com/moleculin-reports-full-year-2025-financial-results-and-confirms-highly-anticipated-45-patient-interim-data-unblinding-in-pivotal-miracle-trial-on-track-for-mid-2026/
Context: Phase 3 adaptive trial of annamycin + cytarabine in relapsed/refractory AML.
Key point: Moleculin reported a preliminary blinded CRc rate of 40% in the first 30 patients; interim unblinding of 45 patients expected mid-2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 BBM-H901 expands gene therapy access in hemophilia B [6] [China/Macao • 19 Mar 2026]

https://www.beliefbiomed.com/en/newsd-857.html
Context: AAV-based gene therapy enabling sustained FIX expression after a single infusion.
Key point: Approved in Macao for moderate-to-severe hemophilia B, following mainland China approval in 2025.
Implication: Signals pipeline investment and modality expansion.

🤝 Belief BioMed partners to commercialize hemophilia A gene therapy [7] [China • 23 Mar 2026]

https://www.prnewswire.com/news-releases/belief-biomed-and-grand-life-sciences-announced-exclusive-commercial-partnership-in-the-field-of-hemophilia-a-bringing-innovative-gene-therapy-to-chinese-patients-302721786.html
Context: BBM-H803 is an investigational gene therapy for hemophilia A.
Key point: Belief BioMed granted Grand Life Sciences commercialization rights across Greater China.
Implication: Signals pipeline investment and modality expansion.

🧪 HUTCHMED launches Phase 3 BTK inhibitor trial in DLBCL [8] [China • 23 Mar 2026]

https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/hutchmed-initiates-phase-iii-trial-of-hmpl-760-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-in-china/2305124
Context: HMPL-760 is a reversible BTK inhibitor targeting wild-type and C481S-mutant BTK.
Key point: First patient dosed in a randomized Phase 3 trial combining HMPL-760 with R-GemOx in relapsed/refractory DLBCL.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Gene therapy scaling challenges surfaced clearly: CSL’s HEMGENIX stockout underscores real-world manufacturing constraints that may limit near-term uptake despite strong clinical value [1].
Checkpoint inhibitors continue frontline expansion: Nivolumab’s approval in Hodgkin lymphoma reinforces the shift toward immunotherapy-based first-line regimens [4].
LATAM oncology access is accelerating: MINJUVI’s approval and filings show rapid regulatory alignment and broader availability of targeted therapies [2][3].
China is advancing both innovation and commercialization: Approvals, partnerships, and Phase 3 starts (BBM, HUTCHMED) highlight ecosystem maturity across gene therapy and small molecules [6][7][8].
AML pipeline remains active but early: Encouraging blinded signals from MIRACLE will need confirmation before impacting clinical practice [5].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

🎯 Catch up on the Top Hematology news from the past two weeks, curated by the LucidQuest team. 🎬 Watch on YouTube.

FAQ

What caused the HEMGENIX supply issue?

CSL stated the temporary stockout is due to manufacturing complexity and maintaining regulatory-quality standards, not safety or efficacy concerns [1].

How significant is the nivolumab frontline approval?

It introduces a PD-1 inhibitor into first-line treatment of advanced Hodgkin lymphoma, with a PFS advantage over brentuximab vedotin-based therapy in a large randomized trial [4].

What is new for MINJUVI in follicular lymphoma?

It is now approved in Brazil and under regulatory review in Argentina and Mexico for relapsed/refractory follicular lymphoma in combination with lenalidomide and rituximab [2][3].

What should we watch in the MIRACLE AML trial?

The mid-2026 interim unblinding of 45 patients will provide the first controlled efficacy signal for annamycin plus cytarabine [5].

How is China progressing in hemophilia gene therapy?

BBM-H901’s approval in Macao expands access beyond mainland China, while partnerships for hemophilia A therapies signal broader pipeline growth [6][7].

Entities / Keywords

HEMGENIX, etranacogene dezaparvovec, CSL, hemophilia B, AAV gene therapy
MINJUVI, tafasitamab, Knight Therapeutics, follicular lymphoma, CD19 antibody
nivolumab, Opdivo, AVD, Hodgkin lymphoma, PD-1 inhibitor
annamycin, cytarabine, MIRACLE trial, relapsed/refractory AML
BBM-H901, dalnacogene ponparvovec, hemophilia B gene therapy
BBM-H803, hemophilia A gene therapy, Belief BioMed
HMPL-760, BTK inhibitor, HUTCHMED, DLBCL